Company Profile

Lumen Bioscience Inc
Profile last edited on: 3/1/2023      CAGE: 7UBN7      UEI: E9UJDT3BFUQ5

Business Identifier: Development of biologic drugs faster at lower cost and reduced risk than traditional methods.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1441 North 34th Street Suite 300
Seattle, WA 98103
   (206) 899-1904
Location: Single
Congr. District: 07
County: King

Public Profile

Making therapeutic biologics for oral delivery, Lumen Biosciences' patented technology allows use of well-known food algae spirulina to deliver therapeutic proteins: ultra-low-cost biologics - one example being antibodies. Specialties: Industrial biotechnology, Cyanobacteria, Pigments, and Animal health. Firm is targeting therapeutics against disease targets that - due to the high cost of traditional methods to make and deliver biologic drugs - have previously been inaccessible to the biopharma industry. Now, for the first time, Lumen can make antibodies and other biologics at a cost that allows for daily, high-dose, oral delivery. Current programs focus on diseases that can be prevented or treated by an orally delivered therapeutic: target markets are extensive; treatment modes of action are well-researched, and the unmet medical need is obvious. Firm has secured financial support for these programs from groups like the Bill & Melinda Gates Foundation and the NIH. In the longer term, management judge that the ability to safely deliver frequent, large doses of a wide range of biologic compounds will become commonplace in biopharma as the science continues to advance and uncover new opportunities in the fields of microbiome signaling, metabolism, inflammation, and oral delivery of systemic biologics.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $2,596,975
Project Title: Development of a Spirulina-Based Oral Malaria Vaccine
2018 1 USDA $99,572
Project Title: Spirulina-based oral vaccine for infectious hematopoietic necrosis virus (IHNV) in farmed salmonid fish

Key People / Management

  Brian Finrow -- Co-founder and CEO

  Craig Behnke -- SVP, Production & Development

  Kristie Keeney -- 3rd Scientist II

  Kole Krieger -- Vice President, Business Development

  Carl Mason -- VP Clinical

  George Montgomery -- Board Member, Investor, Corporate Finance - CFO

  Mesfin Mulugeta Gewe -- Senior Scientist

  Sean Christopher Murphy

  Jim Roberts -- Founder & CSO

  Don Schlosser -- CFO

  Michael Tasch

  Cristin Wagner -- VP, Head of Legal

Company News

There are no news available.